PDF(Pubmed)
Abstract：
Musculoskeletal disorders (MSDs) are widespread in many countries and their huge burden on the society has necessitated innovative approaches such as digital health interventions. However, no study has evaluated the findings of cost-effectiveness of these interventions.
This study aims to synthesize the cost-effectiveness of digital health interventions for people with MSDs.
Electronic databases including MEDLINE, AMED, CIHAHL, PsycINFO, Scopus, Web of Science, and Centre for Review and Dissemination were searched for cost-effectiveness of digital health published between inception and June 2022 following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. References of all retrieved articles were checked for relevant studies. Quality appraisal of the included studies was performed using the Quality of Health Economic Studies (QHES) instrument. Results were presented using a narrative synthesis and random effects meta-analysis.
A total of 10 studies from 6 countries met the inclusion criteria. Using the QHES instrument, we found that the mean score of the overall quality of the included studies was 82.5. Included studies were on nonspecific chronic low back pain (n=4), chronic pain (n=2), knee and hip osteoarthritis (n=3), and fibromyalgia (n=1). The economic perspectives adopted in the included studies were societal (n=4), societal and health care (n=3), and health care (n=3). Of the 10 included studies, 5 (50%) used quality-adjusted life-years as the outcome measures. Except 1 study, all the included studies reported that digital health interventions were cost-effective compared with the control group. In a random effects meta-analysis (n=2), the pooled disability and quality-adjusted life-years were -0.176 (95% CI -0.317 to -0.035; P=.01) and 3.855 (95% CI 2.023 to 5.687; P<.001), respectively. The meta-analysis (n=2) for the costs was in favor of the digital health intervention compared with control: US $417.52 (95% CI -522.01 to -313.03).
Studies indicate that digital health interventions are cost-effective for people with MSDs. Our findings suggest that digital health intervention could help improve access to treatment for patients with MSDs and as a result improve their health outcomes. Clinicians and policy makers should consider the use of these interventions for patients with MSDs.
PROSPERO CRD42021253221; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=253221.
This study aims to synthesize the cost-effectiveness of digital health interventions for people with MSDs.
Electronic databases including MEDLINE, AMED, CIHAHL, PsycINFO, Scopus, Web of Science, and Centre for Review and Dissemination were searched for cost-effectiveness of digital health published between inception and June 2022 following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. References of all retrieved articles were checked for relevant studies. Quality appraisal of the included studies was performed using the Quality of Health Economic Studies (QHES) instrument. Results were presented using a narrative synthesis and random effects meta-analysis.
A total of 10 studies from 6 countries met the inclusion criteria. Using the QHES instrument, we found that the mean score of the overall quality of the included studies was 82.5. Included studies were on nonspecific chronic low back pain (n=4), chronic pain (n=2), knee and hip osteoarthritis (n=3), and fibromyalgia (n=1). The economic perspectives adopted in the included studies were societal (n=4), societal and health care (n=3), and health care (n=3). Of the 10 included studies, 5 (50%) used quality-adjusted life-years as the outcome measures. Except 1 study, all the included studies reported that digital health interventions were cost-effective compared with the control group. In a random effects meta-analysis (n=2), the pooled disability and quality-adjusted life-years were -0.176 (95% CI -0.317 to -0.035; P=.01) and 3.855 (95% CI 2.023 to 5.687; P<.001), respectively. The meta-analysis (n=2) for the costs was in favor of the digital health intervention compared with control: US $417.52 (95% CI -522.01 to -313.03).
Studies indicate that digital health interventions are cost-effective for people with MSDs. Our findings suggest that digital health intervention could help improve access to treatment for patients with MSDs and as a result improve their health outcomes. Clinicians and policy makers should consider the use of these interventions for patients with MSDs.
PROSPERO CRD42021253221; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=253221.
摘要：
背景：肌肉骨骼疾病（MSD）在许多国家普遍存在，其对社会的巨大负担需要创新方法，例如数字健康干预措施。然而,尚无研究评估这些干预措施的成本-效果.
目的：本研究旨在综合数字健康干预措施对MSD患者的成本效益。
方法：电子数据库，包括MEDLINE，AMED,CIHAHL,PsycINFO,Scopus,WebofScience,根据PRISMA（系统审查和荟萃分析的首选报告项目）指南，对审查和传播中心在开始至2022年6月之间发布的数字健康的成本效益进行了搜索。检查所有检索到的文章的参考文献以进行相关研究。使用健康经济学研究质量（QHES）仪器对纳入研究进行质量评估。结果采用叙述性综合和随机效应荟萃分析。
结果：共有来自6个国家的10项研究符合纳入标准。使用QHES仪器，我们发现纳入研究的总体质量平均得分为82.5.纳入的研究包括非特异性慢性下腰痛（n=4），慢性疼痛（n=2），膝关节和髋关节骨关节炎（n=3），和纤维肌痛（n=1）。纳入研究的经济观点是社会的(n=4)，社会和医疗保健(n=3)，医疗保健（n=3）。在纳入的10项研究中，5（50％）使用质量调整的生命年作为结果指标。除了1项研究,所有纳入的研究均报道,与对照组相比,数字健康干预措施具有成本效益.在随机效应荟萃分析(n=2)中，合并的残疾和质量调整生命年分别为-0.176（95％CI-0.317至-0.035；P=0.01）和3.855（95％CI2.023至5.687；P<.001），分别。与对照组相比，成本的荟萃分析（n=2）有利于数字健康干预：417.52美元（95％CI-522.01至-313.03）。
结论：研究表明，数字健康干预措施对MSD患者具有成本效益。我们的研究结果表明，数字健康干预可以帮助改善MSD患者获得治疗的机会，从而改善他们的健康结果。临床医生和政策制定者应考虑对MSD患者使用这些干预措施。
背景：PROSPEROCRD42021253221;https://www.crd.约克。AC.uk/prospro/display_record.php?RecordID=253221。
目的：本研究旨在综合数字健康干预措施对MSD患者的成本效益。
方法：电子数据库，包括MEDLINE，AMED,CIHAHL,PsycINFO,Scopus,WebofScience,根据PRISMA（系统审查和荟萃分析的首选报告项目）指南，对审查和传播中心在开始至2022年6月之间发布的数字健康的成本效益进行了搜索。检查所有检索到的文章的参考文献以进行相关研究。使用健康经济学研究质量（QHES）仪器对纳入研究进行质量评估。结果采用叙述性综合和随机效应荟萃分析。
结果：共有来自6个国家的10项研究符合纳入标准。使用QHES仪器，我们发现纳入研究的总体质量平均得分为82.5.纳入的研究包括非特异性慢性下腰痛（n=4），慢性疼痛（n=2），膝关节和髋关节骨关节炎（n=3），和纤维肌痛（n=1）。纳入研究的经济观点是社会的(n=4)，社会和医疗保健(n=3)，医疗保健（n=3）。在纳入的10项研究中，5（50％）使用质量调整的生命年作为结果指标。除了1项研究,所有纳入的研究均报道,与对照组相比,数字健康干预措施具有成本效益.在随机效应荟萃分析(n=2)中，合并的残疾和质量调整生命年分别为-0.176（95％CI-0.317至-0.035；P=0.01）和3.855（95％CI2.023至5.687；P<.001），分别。与对照组相比，成本的荟萃分析（n=2）有利于数字健康干预：417.52美元（95％CI-522.01至-313.03）。
结论：研究表明，数字健康干预措施对MSD患者具有成本效益。我们的研究结果表明，数字健康干预可以帮助改善MSD患者获得治疗的机会，从而改善他们的健康结果。临床医生和政策制定者应考虑对MSD患者使用这些干预措施。
背景：PROSPEROCRD42021253221;https://www.crd.约克。AC.uk/prospro/display_record.php?RecordID=253221。
